Research
Accelerating Progress through Diversity and Speed in Clinical Trial Accrual
Our network connects leading hospitals and health systems across the country through a coordinated clinical and research framework, enabling broad access to world?class cancer care and innovative clinical research.
Our network of partners offers:
- Strong oncology programs, dedicated research staff and the infrastructure needed to conduct groundbreaking multicenter studies
- Ability to capture more early-stage disease, rare tumor types and to reach more patients, enabling discoveries that are more relevant to the populations impacted by the disease
About us
Partner institutions work strategically through our program to activate multicenter clinical trials that are scientifically rigorous, financially sustainable and aligned with the needs of local patient populations.
Each partner institution brings unique strengths and aligns clinically and operationally with UT MD Anderson, applying the same treatment approaches, protocols and practice standards set by UT MD Anderson.
Through this integration, patients benefit from a diverse range of research options¡ªclose to home.
Joint projects have opened, completed accrual and published quickly with excellent data quality and protocol compliance.
To streamline and accelerate study startup, a clinical trials agreements solution is in place to enable one single contract and one budget to simultaneously activate sponsored trials at UT MD Anderson in Houston and at our partner locations.
Together, we have a proven record to accelerate clinical trial accrual and new discoveries.
Partners
Our network combines the strengths of multiple institutions into a cohesive whole. See a listing of our current partner sites.
Impact & publications
The research trial pipeline is continually expanding, with new trials and site activations ongoing.
Recent network studies have launched more efficiently as a result of coordinated planning, clear communication and early identification of operational needs. The research environment is built for scale, speed and scientific excellence.
This integrated model grounded in UT MD Anderson¡¯s scientific leadership and operational expertise supports faster decision?making, improved trial readiness and more efficient enrollment.
Browse peer-reviewed publications and media highlighting results from trials in our network.
Our network by the numbers
- Seven high-performing partner institutions with 37,000 cases. Comprehensive, dedicated facilities are equipped and ready to conduct multicenter trials
- More than 800 actively engaged physicians across oven 60 participating locations: Greater access to treatment-naive patients and broader access to rare tumor types
- 5,000+ patients participated in nearly 30 UT MD Anderson-led research projects since 2017. Variety of populations enrolled with black, Hispanic, and female participation. Greater age distribution of participants.
Trusted Operations Support
Research in our network represents a productive engagement between partners and UT MD Anderson in Houston. The approach centers on managing a site-relevant, treatment-focused trial portfolio.
Site investigators and study teams receive programmatic support from our faculty-led, experienced, and dedicated team based at UT MD Anderson in Houston with a focus on:
- Scientifically -focused disease working groups to advance the most high-impact trials across multiple specialties
- Partner trial referral to improve local research access
- Educational opportunities to enhance innovation
- Partner collaborative meetings for making long-lasting connections
- Advisory services for strategic program growth, and more
For more information for research sponsors or to collaborate with the network, please contact CancerNetworkResearch@mdanderson.org.
UT MD Anderson PIs endorsing network collaboration
Extending Reach
¡°Together, our work [through our network] aligns with UT MD Anderson¡¯s strategic plan, extending the reach of my clinical trial and facilitating breakthroughs from the knowledge gained from my practice-changing trial.¡±
Professor, Breast Radiation Oncology, UT MD Anderson
Accelerating Accrual
¡°Because of our cancer network¡¯s involvement, trials reach accrual more quickly ensuring much needed high-quality results sooner for patients with breast cancer.¡±
Professor, Breast Surgical Oncology, UT MD Anderson
Advancing Breakthroughs
¡°I believe our cancer network research program brings hope by helping discoveries reach patients sooner and giving more people access to promising new anticancer treatments through clinical trials.¡±
Assistant Professor, Investigational Cancer Therapeutics, UT MD Anderson
Published Trials in Our Network
About our publications
Last updated July 2026
Browse publications and media highlighting results from the 16 published trials in our network.
Listed authors include UT MD Anderson lead principal investigator if author, first author if different from UT MD Anderson lead principal investigator, and authors representing all sites in the network at the time of the study.
Peer-reviewed articles: trials conducted in our network
DISEASE SITE: COLORECTAL
MiRDA - clinicaltrials.gov page:
Dasari, Arvind; Acoba, Jared David; Dragovich, Tomislav; Zaiden, Robert Anthony, et al.
Journal of Clinical Oncology, 2022, Vol.40 (4_suppl), p.TPS236-TPS236
DISEASE SITE: BREAST
Exceptional Responders -
Kuerer, Henry M, et al.
JAMA Oncology, 2025-03
Johnson, Helen M.; Kuerer, Henry M, et al.
JAMA Network Open, 2023-09, Vol.6 (9), p.e2333933
Johnson, Helen M; Kuerer, Henry M, et al.
Journal of the American College of Surgeons, 2023-07, Vol.237 (1), p.101-108
Kuerer, Henry M; Samiian, Laila; Lesnikoski, Beth-Ann; Chong, Clayton; Loveland-Jones, Catherine, et al.
The Lancet Oncology, 2022, Vol.23 (12), p.1517-1524
Financial Toxicity -
Smith, Grace L., et al.
Breast (Edinburgh), 2024-12, Vol.78, p.103813-103813, Article 103813
OPAL I ¨C
Reddy, Jay P.; Smith, Benjamin D.; Weed, Daniel W; Anderson, Cynthia, et al.
International Journal of Radiation Oncology, Biology, Physics, 2023, Vol.115 (3), p.629-644
Registry - Axillary Nodal Metastases
Loveland-Jones, Catherine; Murphy, Brittany; Samiian, Laila; Byrum, Stephanie; Kuerer, Henry, et al.
European Journal of Surgical Oncology, 2024-04, Vol.50 (4), p.108245-108245, Article 108245
SAPHIRe -
Hoffman, K.E., et al.
International Journal of Radiation Oncology, Biology, Physics, 2024-10, Vol.120 (2), p.S14-S15
DISEASE SITE: HEAD & NECK
3D Stent -
Tino, Rance B.; Mezera, Megan; Mann, Justin M.; Augspurger, Mark; Lee, Anna, et al.
Oral Oncology, 2025-03, Vol.162, p.107220-107220, Article 107220
Tino, Rance B.; Mezera, Megan; Mann, Justin M.; Augspurger, Mark; Koay, Eugene; Lee, Anna, et al.
Oral Oncology, 2024-10, Vol.157, p.106944-106944, Article 106944
DISEASE SITE: LUNG
LEAP
Dennison, Jennifer B.; Godoy, Myrna C.B.; Michael; Grainger, Andrew; Shersher, Putnam, Joe B., et al.
Cancer Epidemiology, Biomarkers & Prevention, 2025-11, Vol.35 (1), p.39
PACIFIC-4 -
Robertson, Clifford; Lin, Steven H, et al.
Journal of Clinical Oncology, 2023 41:16_suppl, TPS8607-TPS8607
VESPA
Salahuddin, Moiz; Sagar, Ala-Eddin S; Casal, Roberto F, et al.
Chest, 2022, Vol.162 (6), p.1393-1401
DISEASE SITE: PROSTATE
EXTEND -
Sherry, Alexander D.; Tang, Chad; Ha, Chul S., et al.
European Urology, 2025-11, Vol.88 (5), p.496-509
Shi, Xiaolei; Tang, Chad, et al.
Prostate Cancer And Prostatic Diseases, 2025-10
Reddy, Jay P.; Weed, Daniel; Tang, Chad, et al.
International Journal of Radiation Oncology, Biology, Physics, 2025-03, Vol.121 (4), p.885-893
Haymaker, Cara L; Tang, Chad, et al.
Journal of Clinical Oncology, 2025-02, Vol.43 (5_suppl), p.140-140
Ludmir, Ethan B.; Tang, Chad, et al.
Journal of Clinical Oncology, 2024-08, p.JCO2400081
v
Tang, Chad, et al.
JAMA Oncol. 2023 Jun 1;9(6):825-834. doi: 10.1001/jamaoncol.2023.0161.
Sherry, Alexander D.; Tang, Chad, et al.
International Journal of Radiation Oncology, Biology, Physics, 2022, Vol.114 (5), p.910-918
DISEASE SITE: UTERINE
LEVER -
Reddy, Ravali; Westin, Shannon, Warshal, David; Clements, Aine; Soliman, Pamela, et al.
International Journal of Gynecological Cancer, 2025-11, Vol.35 (11), p.102141, Article 102141
Westin, Shannon N.; Fellman, Bryan; Sun, Charlotte C.; Broaddus, Russell R.; Woodall, Misty L.; Pal, Navdeep; Urbauer, Diana L.; Ramondetta, Lois M.; Schmeler, Kathleen M.; Soliman, Pamela T.; Fleming, Nicole D.; Burzawa, Jennifer K.; Nick, Alpa M.; Milbourne, Andrea M.; Yuan, Ying; Lu, Karen H.; Bodurka, Diane C.; Coleman, Robert L.; Yates, Melinda S.
American journal of obstetrics and gynecology, 2021-02, Vol.224 (2), p.191.e1-191.e15
DISEASE SITE: BREAST, OVARIAN, COLORECTAL
Genetic Test Result Variants
Makhnoon, Sukh; Samiian, Laila; Grana, Generosa; Grainger, Andrew; Peterson, Susan K., et al.
Cancer Medicine (Malden, MA), 2023, Vol.12 (3), p.2875-2884
Makhnoon, Sukh; Samiian, Laila; Grana, Generosa; Grainger, Andrew V.; Peterson, Susan K., et al.
Journal of Clinical Oncology, 2022-06, Vol.40 (16_suppl), p.10512-10512
PHASE 1 CLINICAL TRIALS
TAPUR -
Al Baghdadi, Meric-Bernstam, Funda, et al.
JCO Precision Oncology, 2025-10, Vol.9 (9), p.e2500649, Article e2500649
Hall, M.J.; Rothe, Meric-Bernstam, F., et al.
Annals of Oncology, 2025-09, Vol.36, p.S617-S618
Schuetze, Scott; Meric-Bernstam, Funda, et al.
JCO Precision Oncology, 2024-07, Vol.8 (8), p.e2400219
Chan, John K; Meric-Bernstam, Funda, et al.
Journal of Clinical Oncology, 2024-06, Vol.42 (16_suppl), p.3130-3130
Khalil, M.F.; Meric-Bernstam, F., et al.
Annals of Oncology, 2023-10, Vol.34, p.S265-S266
Rohatgi, Nitin; Meric-Bernstam, Funda, et al.
JCO Precision Oncology, 2023-09, Vol.7 (7), p.e2300279
Meric-Bernstam, Funda, et al.
JCO Precision Oncology, 2023-09, Vol.7 (7), p.e2300385
Gupta, Ranju; Meric-Bernstam, Funda, et al.
JCO Precision Oncology, 2022-10, Vol.6 (6), p.e2200306
Ahn, E.; Meric-Bernstam, F., et al.
Annals of Oncology, 2022-09, Vol.33, p.S583-S584
Meric-Bernstam, Funda, et al.
Journal of Clinical Oncology, 2022-06, Vol.40 (16_suppl), p.3008-3008
Schuetze, Scott; Meric-Bernstam, Funda, et al.
Journal of Clinical Oncology, 2021-05, Vol.39 (15_suppl), p.11565-11565
CANCER AND COVID
Issam I Raad, Bilal Siddiqui, Robert Somer, Edward Gorak, Arvinder Bhinder, Samuel Shelanski, Tomislav Dragovich, et al.
eLife, 2023, 12:e81127
Other network contributions
PEER REVIEWED SUMMARIES AT ANNUAL MEETINGS
EXTEND
Disease site: Prostate
Gourd, Katherine
The Lancet, Oncology, 2022, Vol.23 (12), p.1490-1491.
Page 1491, Metastasis-directed therapy EXTENDs progression-free survival, results presented by Chad Tang
NEWS RELEASES
3D Stent
Disease site: Head and Neck
BioSpace, Jan 18, 2024
EXTEND
Disease site: Prostate
The American Society for Radiation Oncology (ASTRO) StaffASTRO targeting cancer care, 2022
UroToday
Sayyid, Rashid during 2022 American Society of Radiation Oncology (ASCO) annual hybrid meeting, San Antonio, TX, Sat, Oct 22 ¨C Wed, Oct 26, 2022
The American Society of clinical oncology, inc. (ASCO?) post staff
The ASCO Post, 2022
POSTERS AND SLIDES
SAPHIRe
Disease site: Breast
Goodman, Chelain; Hoffman, Karen E., et al.
Clinical Cancer Research, 2025-06, Vol.31 (12_Supplement), p.PS6-02-PS6-02
AxDev
Disease site: Lung and Thyroid
Subbiah, V, et al.
Slides from interdisciplinary workshop, released Nov 16, 2023
TAPUR
Disease area: Phase I
Srkalovic, Gordan; Meric-Bernstam, Funda; et al.
Cancer Research (Chicago, Ill.), 2025-04, Vol.85 (8_Supplement_2), p.CT226-CT226
Mileham, Kathryn F.; Meric-Bernstam, Funda, et al.
Cancer Research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT110-CT110
UT MD ANDERSON INVESTIGATOR VIDEOS
EXTEND
Prostate
Tang, Chad
Video, Urology Times, 2023
Tang, Chad
Video, Targeted Oncology, 2022
Tang, Chad
Video, The Video Journal of Oncology, 2022
LAY PRESS
Exceptional Responders
Breast
Rabin, Roni Caryn. : In a small trial, chemotherapy alone was sufficient to treat women with certain kinds of tumors. New York Times, Oct 25, 2022.
PEER REVIEWED ARTICLES - TRIALS WITH RELATED NETWORK COLLABORATION
Disease site: Hematologic
Pemmaraju, Naveen, et al.
Blood, 2023-02, Vol.141 (6), p.567-578